February 12, 2025 03:39 PM EST

NIH’s funding cut plan poses challenges for researchers despite court halt

Nicole DeFeudis

Editor

An NIH cap on indirect cost payments for grant recipients is casting a shroud of uncertainty for research universities despite a judge’s order to block …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

NIH’s funding cut plan poses challenges for researchers despite court halt

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

AbbVie pens another T cell engager deal, this time with Xilio

AnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis

Biogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Kaiser Permanente calls on FDA and Congress to firm up accelerated approval requirements

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

NIH’s fund­ing cut plan pos­es chal­lenges for re­searchers de­spite court halt

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

NIH’s funding cut plan poses challenges for researchers despite court halt